WECElbert296866 at 02:27, 17 August 2025

2025-08-17T02:27:51Z

New page

{{Short description|Indian pharmaceutical and healthcare products company}}
{{Use dmy dates|date=April 2015}}
{{Use Indian English|date=April 2015}}
{{Infobox company
| name = Mankind Pharma Limited
| logo = Mankind Pharma Corporate Logo.png
| type = [[Public company|Public]]
| traded_as = {{ubl|{{NSE|MANKIND}}|{{BSE|543904}}}}
| ISIN = INE634S01028
| founders = {{plainlist|
*[[R C Juneja|Ramesh C. Juneja]]
*Rajeev Juneja<ref>{{cite news |last1=Bhalla |first1=Mohit |last2=Rajagopal |first2=Divya |title=Mankind Pharma: The story of Juneja siblings, the biggest disruptors in Indian pharma space |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/the-story-of-juneja-siblings-the-biggest-disruptors-in-indian-pharma-space/articleshow/63687453.cms |access-date=21 December 2022 |work=The Economic Times}}</ref>}}
| foundation = {{Start date and age|1991}}
| area_served = Worldwide
| location_city = [[Okhla]] Phase III, [[Delhi]]
| location_country = [[India]]<ref>{{cite news |last1=Singh |first1=Khomba |title=Mankind Pharma's pocket-friendly pricing in demand |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mankind-pharmas-pocket-friendly-pricing-in-demand/articleshow/5258576.cms |access-date=21 December 2022 |work=The Economic Times}}</ref>
| industry = [[Pharmaceutical Industry|Pharmaceutical]]
| products = {{hlist
|[[Pharmaceuticals]]
|[[Generic drugs]]
|[[Over-the-counter drug|OTC]]
|[[Fast-moving consumer goods|FMCG]]
|[[Diagnostics]]}}
| subsid =
| key_people = {{plainlist|
*Ramesh Juneja ([[Chairman]])
*Rajeev Juneja ([[Managing director|MD]] & Vice Chairman)
*Sheetal Arora ([[Chief executive officer|CEO]])
*Arjun Juneja ([[Chief operating officer|COO]])}}
| revenue = {{up}} {{INRConvert|12207|c}} (2025)
| operating_income = {{up}} {{INRConvert|3030|c}} (2025)
| net_income = {{up}} {{INRConvert|2007|c}} (2025)
| assets = {{up}} {{INRConvert|27759|c}} (2025)
| equity = {{up}} {{INRConvert|14568|c}} (2025)
| homepage = {{official URL}}
| num_employees = 22,000+ (2023)<ref>{{cite news |title=Mankind Pharma Forays Into Critical Care Segment |url=https://www.outlookindia.com/business/mankind-pharma-forays-into-critical-care-segment-news-42792 |access-date=12 April 2023 |work=Outlook India}}</ref>
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Investor Presentation Q4 & FY25 |url=https://www.mankindpharma.com/wp-content/uploads/2025/05/Investor_Presentation_sd.pdf |access-date=24 May 2025 |work=Mankind Pharma}}</ref><ref>{{cite web |title=Statement of audited consolidated financial results for the quarter and year ended March 31, 2025 |url=https://www.mankindpharma.com/wp-content/uploads/2025/05/Outcome_sd.pdf |publisher=Mankind Pharma |access-date=24 May 2025}}</ref>
}}

'''Mankind Pharma''' is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] and [[Health care|healthcare product]] company, headquartered in [[Delhi]]. The company has products in therapeutic areas ranging from [[antibiotics]], to [[gastrointestinal]], [[cardiovascular]], [[dermal]], and [[erectile dysfunction]] medications.<ref>{{cite news |title=India's Mankind Pharma wants deals, sees FY domestic sales topping $700 mln |url=https://www.reuters.com/article/mankindpharma-deals-india-idINL4N0X53SA20150410 |access-date=21 March 2023 |work=Reuters |date=10 April 2015 |language=en}}</ref><ref>{{cite news |last1=Raturi |first1=Prerna |title=For a robust business |url=http://business-standard.com/india/news/forrobust-business/157711/on/ |access-date=7 May 2023 |work=Business Standard |date=11 February 2012 |archive-url=https://web.archive.org/web/20120427115436/http://business-standard.com/india/news/forrobust-business/157711/on/ |archive-date=27 April 2012}}</ref><ref>{{cite news |last1=Singh |first1=Raveena |title=At $6-7B, Mankind Pharma eyes Torrent's valuation. But its catch lies in Eris & Gland IPOs |url=https://the-ken.com/story/at-6-7b-mankind-pharma-eyes-torrents-valuation-but-its-catch-lies-in-eris-gland-ipos/ |access-date=21 March 2023 |work=The Ken |date=20 March 2023}}</ref>

As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India.<ref name="forbes"/> The company derived 97% of its operating revenue from the Indian market,<ref>{{cite news |title=India's biggest condom maker lifts dreary IPO market |url=https://www.ft.com/content/4cbf7635-2c51-4be4-811f-283fc1d436b2 |access-date=4 December 2023 |work=Financial Times|date=27 April 2023}}</ref> where it is reportedly the fourth largest pharmaceutical company by domestic sales.<ref name="forbes">{{cite news |last1=Raghunathan |first1=Anu |title=Mankind Pharma's Founders Map Growth Plan After Pulling Off Major IPO |url=https://www.forbes.com/sites/anuraghunathan/2023/10/11/mankind-pharmas-founders-map-growth-plan-after-pulling-off-major-ipo |access-date=4 December 2023 |work=Forbes |date=11 October 2023|language=en}}</ref> Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in [[condom]]s,<ref>{{cite news |last1=Tandon |first1=Suneera |title=Durex becomes second-largest condom brand in India: Reckitt |url=https://www.livemint.com/companies/news/durex-becomes-the-second-largest-condom-brand-in-india-reckitt-11645165033746.html |access-date=22 November 2022 |work=Mint |date=18 February 2022 |language=en}}</ref> Prega News in [[pregnancy test|pregnancy test kits]],<ref>{{cite news |title=Behind Mankind's plans to take Prega News to rural markets |url=https://www.moneycontrol.com/news/business/storyboard18-behind-mankinds-plans-to-take-prega-news-to-rural-markets-7690841.html |access-date=22 November 2022 |work=Moneycontrol |language=en}}</ref> and Unwanted-72 in [[emergency contraception]].<ref>{{cite news |title=Mankind Pharma Ltd. |url=https://reports.chittorgarh.com/ipo_notes/Mankind-Pharma-IPO-Analysis-Geojit-Securities.pdf |access-date=24 April 2023 |work=Geojit }}{{Dead link|date=August 2025 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>

== History ==
[[File:Spicejet 737-800 special livery "Prega News" at Bangalore Airport (38764400805).jpg|thumb|Prega News livery on a [[SpiceJet]] aircraft.]]
Mankind Pharma was incorporated in 1991, and actively started its operations in 1995, with the contributions of two brothers, [[R C Juneja|Ramesh C. Juneja]] and Rajeev Juneja, who established the company with a seed capital of {{currency|5000000|INR}}.<ref>{{cite web|url=http://forbesindia.com/article/boardroom/mankind-pharma-formulating-strategy-to-enter-the-big-league/37704/0 |title=Mankind Pharma: Formulating Strategy To Enter The Big League |date=8 May 2014|first1=Shabana|last1=Hussain|access-date=27 June 2018}}</ref><ref>{{cite news |title=Mankind Pharma set to tap core drugs market |url=http://www.business-standard.com/article/companies/mankind-pharma-set-to-tap-core-drugs-market-112071900076_1.html |access-date=26 April 2023 |work=Business Standard |date=19 July 2012 |archive-url=https://web.archive.org/web/20141006171322/http://www.business-standard.com/article/companies/mankind-pharma-set-to-tap-core-drugs-market-112071900076_1.html |archive-date=6 October 2014}}</ref> The company was started with 20 employees and launched in two states in the first year of its operation.<ref>{{cite web |url=http://business.outlookindia.com/article.aspx?279322 |title=A Giant Leap For Mankind |publisher=Business Outlook India |date=2011-12-24 |access-date=2013-02-05 |url-status=dead |archive-url=https://web.archive.org/web/20120629041707/http://business.outlookindia.com/article.aspx?279322 |archive-date=29 June 2012 |df=dmy-all }}</ref><ref>{{cite news |title=Testing Times For Mankind Pharma |url=https://www.businessworld.in/article/Testing-Times-For-Mankind-Pharma/08-11-2014-69709/ |access-date=26 April 2023 |work=Businessworld |language=en}}</ref>

Mankind Pharma initially targeted price-sensitive drugs, with a focus on rural market;<ref>{{cite news |last1=Rajagopal |first1=Divya |title=How Ramesh Juneja's Mankind Pharma has changed pharma game with pulp marketing |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/how-ramesh-junejas-mankind-pharma-has-changed-pharma-game-with-pulp-marketing/articleshow/14073528.cms |access-date=1 March 2023 |work=The Economic Times |date=13 June 2012}}</ref> its early products included antibacterial drug Zenflox and prescription antibiotic Moxikind CV, which were priced at a steep discount to the existing products in the market.<ref>{{cite news |title=Mankind vs Goliaths |url=https://www.business-standard.com/article/management/mankind-vs-goliaths-109110300043_1.html |access-date=26 April 2023 |work=Business Standard |date=3 November 2009}}</ref> The company ventured into the [[over-the-counter]] segment in 2007, focusing primarily on sexual healthcare products.<ref>{{cite news |last1=Singh |first1=Khomba |title=Mankind forays into OTC market |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mankind-forays-into-otc-market/articleshow/1716408.cms |access-date=27 April 2023 |work=The Economic Times |date=3 March 2007}}</ref><ref>{{cite news |last1=Singh |first1=Rajiv |title=Mankind Pharma: Do products revolving around sex help the Rs 3000 cr company? |url=https://economictimes.indiatimes.com/mankind-pharma-do-products-revolving-around-sex-help-the-rs-3000-cr-company/articleshow/32667512.cms |access-date=26 April 2023 |work=The Economic Times |date=26 March 2014}}</ref>

The company acquired Magnet Labs Pvt. Ltd. to enter the antipsychotic segment in 2007.<ref>{{cite journal |journal=The International Journal of Business Management and Technology |issn=2581-3889 |url=http://www.ijbmt.com/issue/333.pdf |title=Acquisition of Magnet Labs }}{{dead link|date=January 2018 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> It acquired Longifene-an appetite stimulant for children in January 2010 which was earlier a brand of [[UCB (company)|UCB]].<ref>[https://web.archive.org/web/20120711023356/http://www.telegraphindia.com/1110829/jsp/frontpage/story_14438208.jsp Mankind Pharma markets Longifene- 29 August 2011]</ref>

In 2017, Mankind Pharma established Pathkind Labs, a provider of diagnostics and healthcare tests.<ref>{{cite news |title=Mankind Pharma forays into diagnostics |url=https://timesofindia.indiatimes.com/business/india-business/mankind-pharma-forays-into-diagnostics/articleshow/57941625.cms |access-date=26 April 2023 |work=The Times of India |date=31 March 2017}}</ref>

In 2019, Mankind became the first Indian company and second only in the world to develop and launch [[Dydrogesterone]], a drug used in high-risk pregnancies and infertility by the brand name Dydroboon.<ref>{{cite news |title=Mankind Pharma launches drug for the treatment of infertility in India |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-launches-drug-for-treatment-of-infertility-in-india/articleshow/72382986.cms |access-date=22 November 2022 |work=The Economic Times}}</ref>

In 2022, Mankind acquired [[Panacea Biotec|Panacea Biotec Pharma]]'s domestic formulations brands in India and Nepal for {{INRconvert|1872|c}}.<ref>{{cite news |title=Mankind Pharma acquires Panacea's domestic formulation brands for Rs 1,872 cr |url=https://www.businesstoday.in/industry/pharma/story/mankind-pharma-acquires-panaceas-domestic-formulation-brands-for-rs-1872-cr-324342-2022-03-01 |access-date=22 November 2022 |work=Business Today |date=1 March 2022 |language=en}}</ref> It then acquired a respiratory treatment product, and an infant skincare brand from [[Dr. Reddy's Laboratories]].<ref>{{cite news |title=Mankind Pharma acquires two derma and respiratory brands from Dr. Reddy's |url=https://www.business-standard.com/article/companies/mankind-pharma-acquires-two-derma-and-respiratory-brands-from-dr-reddy-s-122021600798_1.html |access-date=22 November 2022 |work=Business Standard}}</ref> It also bought a majority stake in the [[Ayurvedic]] and herbal products manufacturer, Upakarma Ayurveda.<ref name="fy22">{{cite news |last1=Mahtta |first1=Priyal |title=Mankind Pharma acquires majority stake in Upakarma Ayurveda |url=https://www.livemint.com/companies/news/mankind-pharma-acquires-majority-stake-in-upakarma-ayurveda-11669635976909.html |access-date=3 December 2022 |work=mint |date=28 November 2022 |language=en}}</ref>

In 2022, the company entered [[agritech]]<ref>{{cite news |title=Mankind Pharma forays into agri-tech space, plans to invest Rs 200 crore |url=https://www.business-standard.com/article/companies/mankind-pharma-forays-into-agri-tech-space-plans-to-invest-rs-200-crore-122040400869_1.html |access-date=1 March 2023 |work=Business Standard |date=5 April 2022 |language=en}}</ref> and [[Pet food|pet care]] segments.<ref>{{cite news |last1=Pilla |first1=Viswanath |title=Mankind Pharma enters pet care segment with launch PetStar brand |url=https://economictimes.indiatimes.com/industry/cons-products/fmcg/mankind-pharma-enters-pet-care-segment-with-launch-petstar-brand/articleshow/96399981.cms |access-date=1 March 2023 |work=The Economic Times |date=21 December 2022}}</ref>

In April 2023, Mankind Pharma launched its [[initial public offering]] (IPO), with existing investors selling {{INRConvert|4326|c}} worth of shares.<ref>{{cite news |last1=Prabhakar |first1=Sai |title=Mankind Pharma IPO: Why it's a promising prescription |url=https://www.thehindubusinessline.com/portfolio/stock-fundamental-analysis-india/mankind-pharma-ipo-why-its-a-promising-prescription/article66763787.ece |access-date=26 April 2023 |work=The Hindu Businessline |date=22 April 2023 |language=en}}</ref>

In 2024, Mankind Pharma acquired a 100% stake in Bharat Serums and Vaccines (BSV) from private equity firm [[Advent International]] for an enterprise value of {{INRconvert|13630|c}}.<ref name="acquires">{{cite news |last1=Das |first1=Sohini |title=Mankind Pharma acquires Bharat Serums and Vaccines for Rs 13,600 crore |url=https://www.business-standard.com/companies/news/mankind-pharma-acquires-bharat-serums-and-vaccines-for-rs-13-600-crore-124072501480_1.html |access-date=9 August 2024 |work=Business Standard |date=26 July 2024}}</ref> The deal included over 2,500 employees joining the company. Mankind also aimed to raise up to ₹10,000 crore through non-convertible [[debenture]]s to support its growth initiatives.<ref name="acquires"/>

==See also==
* [[Pharmaceutical industry in India]]

== References ==
{{Reflist|30em}}

== External links ==
* {{Official website|http://www.mankindpharma.com/}}
* [https://www.ibm.com/case-studies/mankind-pharma-it-infrastructure-sap Mankind Pharma] at [[IBM]]

{{Authority control}}

[[Category:Generic drug manufacturers]]
[[Category:Manufacturing companies based in Delhi]]
[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies established in 1991]]
[[Category:Indian brands]]
[[Category:Indian companies established in 1991]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:2023 initial public offerings]]

Mankind Pharma - Revision history

WECElbert296866 at 02:27, 17 August 2025